SS
CPRX

SBI Securities’s Catalyst Pharmaceutical CPRX Stock Holding History

SBI Securities’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.7K Buy
756
+27
+4% +$643 ﹤0.01% 1484
2025
Q4 		$17K Buy
729
+309
+74% +$6.88K ﹤0.01% 1508
2025
Q3 		$8.27K Buy
420
+11
+3% +$226 ﹤0.01% 1852
2025
Q2 		$8.88K Sell
409
-124
-23% -$2.93K ﹤0.01% 1753
2025
Q1 		$12.9K Buy
533
+155
+41% +$3.49K ﹤0.01% 1497
2024
Q4 		$7.89K Buy
+378
New +$8.12K ﹤0.01% 1744

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SBI Securities's CPRX Position: Q1 2026 in Review

SBI Securities increased its Catalyst Pharmaceutical (CPRX) stake by 3.7% in Q1 2026, buying an estimated $643 and bringing the position to 756 shares worth $18.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1484.

SBI Securities first reported a position in CPRX in Q4 2024 and has held it in 6 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • SBI Securities held 756 shares of Catalyst Pharmaceutical worth $18.7K as of Q1 2026.
  • SBI Securities bought 27 Catalyst Pharmaceutical shares in Q1 2026, an estimated $643.
  • Catalyst Pharmaceutical made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #1484 holding.
  • SBI Securities first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 6 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.